CVR: 29918791
Previous names: CADENZA PARTNERS ApS, ASCENDIS PHARMA ApS
ASCENDIS PHARMA A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA ApS and CADENZA PARTNERS ApS. The management consists of Michael Wolff Jensen, Jan Møller Mikkelsen and Anni Lotte Kirstine Pedersen. The company is owned by Cede & Co. The company has 108 employees. In 2025, the company reported revenue of DKK 720,132,000 and a net result of DKK -228,034,000 compared with DKK -378,084,000 the year before. Equity amounted to DKK -162,821,000.
The financial health of ASCENDIS PHARMA A/S appears to be concerning, marked by significant losses and declining equity over the past few years. Revenue has shown a substantial increase from 7.8 million DKK in 2021 to 720.1 million DKK in 2025, but this growth has not translated into profitability, with losses reaching -228 million DKK in 2025. The company's equity has deteriorated from 883.6 million DKK in 2021 to -162.8 million DKK in 2025, raising concerns about its financial stability and ability to sustain operations. As it operates in the pharmaceutical manufacturing sector, the trajectory suggests a need for strategic adjustments to improve margins and address its negative equity position.
AI-generated summary
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at udvikle idèer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller idèer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 720.1 mio. | -228 mio. | 1.3 mia. | -162.8 mio. | 1103 | |
| 2024 | 363.6 mio. | -378.1 mio. | 1.2 mia. | -105.7 mio. | 892 | |
| 2023 | 266.7 mio. | -481.4 mio. | 825.6 mio. | -145.7 mio. | 851 | |
| 2022 | 51.2 mio. | -583.2 mio. | 1.1 mia. | 263.3 mio. | 719 | |
| 2021 | 7.8 mio. | -383.6 mio. | 1.1 mia. | 883.6 mio. | - | |
| 2020 | 7 mio. | -419 mio. | 979.8 mio. | 838.7 mio. | - | |
| 2019 | 13.4 mio. | -218 mio. | 676.7 mio. | 597.1 mio. | - | |
| 2018 | 10.6 mio. | -130.1 mio. | 319 mio. | 280.1 mio. | - | |
| 2017 | 1.5 mio. | -123.9 mio. | 211 mio. | 187.2 mio. | - | |
| 2016 | 4.6 mio. | -68.5 mio. | 190.1 mio. | 176.6 mio. | - | |
| 2015 | 8.1 mio. | -32.9 mio. | 131.8 mio. | 120.3 mio. | - | |
| 2014 | 14 mio. | -9.7 mio. | 58.7 mio. | 45.8 mio. | - | |
| 2012 | 118.5 mio. | 8.9 mio. | 202.8 mio. | 134.6 mio. | 38 |
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
1 public tender won
Sources: TED (the EU tender database) and udbud.dk
Screen owners and management against the Danish FSA's official PEP lists
Contact info changed: new phone: 36944486 (July 15, 2026).
Contact info changed: new phone: 36944486 (June 29, 2026).
Contact info changed: new phone: 36944486 (June 26, 2026).
Contact info changed: new phone: 36944486 (June 25, 2026).
Contact info changed: new phone: 36944486 (June 24, 2026).
Contact info changed: new phone: 36944486 (June 23, 2026).
Contact info changed: new phone: 36944486 (June 22, 2026).
Contact info changed: new phone: 36944486 (June 17, 2026).
Contact info changed: new phone: 36944486 (June 16, 2026).
Contact info changed: new phone: 36944486 (June 11, 2026).
Contact info changed: new phone: 36944486 (June 10, 2026).
Contact info changed: new phone: 36944486 (June 8, 2026).
Contact info changed: new phone: 36944486 (June 4, 2026).
Contact info changed: new phone: 36944486 (June 3, 2026).
Contact info changed: new phone: 36944486 (June 2, 2026).
Contact info changed: new phone: 36944486 (June 1, 2026).
Contact info changed: new phone: 36944486 (May 29, 2026).
Contact info changed: new phone: 36944486 (May 28, 2026).
Contact info changed: new phone: 36944486 (May 27, 2026).
Contact info changed: new phone: 36944486 (May 26, 2026).
Contact info changed: new phone: 36944486 (May 22, 2026).
Contact info changed: new phone: 36944486 (May 21, 2026).
Contact info changed: new phone: 36944486 (May 20, 2026).
Contact info changed: new phone: 36944486 (May 19, 2026).
Contact info changed: new phone: 36944486 (May 18, 2026).
Contact info changed: new phone: 36944486 (May 13, 2026).
Contact info changed: new phone: 36944486 (May 12, 2026).
Contact info changed: new phone: 36944486 (May 5, 2026).
Contact info changed: new phone: 36944486 (May 4, 2026).
As of April 20, 2026, is registered as an owner of ASCENDIS PHARMA A/S with an ownership share of 90%.
Contact info changed: new phone: 36944486 (April 15, 2026).
ASCENDIS PHARMA A/S has published its annual report for 2025. Revenue came to DKK 720,132,000, and the net result was DKK -228,034,000.
Contact info changed: new phone: 36944486 (March 30, 2026).
Contact info changed: new phone: 36944486 (March 26, 2026).
Contact info changed: new phone: 36944486 (March 25, 2026).
Contact info changed: new phone: 36944486 (March 24, 2026).
Contact info changed: new phone: 36944486 (March 23, 2026).
Contact info changed: new phone: 36944486 (March 23, 2026).
As of March 23, 2026, Jean-Jacques Bienaime has joined the board of directors of ASCENDIS PHARMA A/S.
Contact info changed: new phone: 36944486 (March 20, 2026).
Contact info changed: new phone: 36944486 (March 19, 2026).
Contact info changed: new phone: 36944486 (March 18, 2026).
Contact info changed: new phone: 36944486 (March 17, 2026).
Contact info changed: new phone: 36944486 (March 16, 2026).
Contact info changed: new phone: 36944486 (March 13, 2026).
Contact info changed: new phone: 36944486 (March 12, 2026).
Contact info changed: new phone: 36944486 (March 11, 2026).
Contact info changed: new phone: 36944486 (March 10, 2026).
Contact info changed: new phone: 36944486 (March 9, 2026).
Contact info changed: new phone: 36944486 (March 6, 2026).
Contact info changed: new phone: 36944486 (March 5, 2026).
Contact info changed: new phone: 36944486 (March 4, 2026).
Contact info changed: new phone: 36944486 (March 3, 2026).
ASCENDIS PHARMA A/S has won the tender "Rammeaftale om køb af Yorvipath (palopegteriparatid)." issued by Amgros I/S worth 305,000,000 DKK.
ASCENDIS PHARMA A/S has published its annual report for 2024. Revenue came to DKK 363,641,000, and the net result was DKK -378,084,000.
ASCENDIS PHARMA A/S has published its annual report for 2023. Revenue came to DKK 266,718,000, and the net result was DKK -481,447,000.
As of November 29, 2023, Rafaèle Tordjman has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2022. Revenue came to DKK 51,174,000, and the net result was DKK -583,194,000.
As of September 9, 2022, Siham Imani has joined the board of directors of ASCENDIS PHARMA A/S.
As of September 9, 2022, William Carl Fairey Jr has joined the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2021. Revenue came to DKK 7,778,000, and the net result was DKK -383,577,000.
As of May 30, 2022, Jim Healy has left the board of directors of ASCENDIS PHARMA A/S.
As of November 18, 2021, Rafaèle Tordjman has joined the board of directors of ASCENDIS PHARMA A/S.
As of October 8, 2021, Anni Lotte Kirstine Pedersen is registered as director of ASCENDIS PHARMA A/S.
As of July 12, 2021, Birgitte Volck has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2020. Revenue came to DKK 6,953,000, and the net result was DKK -418,955,000.
As of May 28, 2021, Albert Cha has joined the board of directors of ASCENDIS PHARMA A/S.
As of May 28, 2021, Michael Wolff Jensen has left the board of directors of ASCENDIS PHARMA A/S.
As of May 28, 2021, Michael Wolff Jensen is registered as director of ASCENDIS PHARMA A/S.
As of May 27, 2021, Albert Cha has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2019. Revenue came to DKK 13,375,000, and the net result was DKK -218,016,000.
ASCENDIS PHARMA A/S has published its annual report for 2018. Revenue came to DKK 10,581,000, and the net result was DKK -130,097,000.
As of November 2, 2018, Lars Holtug has joined the board of directors of ASCENDIS PHARMA A/S.
As of September 12, 2018, Martin Olin has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2017. Revenue came to DKK 1,530,000, and the net result was DKK -123,897,000.
As of May 29, 2018, Jonathan Silverstein has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2016. Revenue came to DKK 4,606,000, and the net result was DKK -68,505,000.
As of May 24, 2017, Lisa Jane Morrison has joined the board of directors of ASCENDIS PHARMA A/S.
As of March 23, 2017, Rafaèle Elisabeth Tordjman has left the board of directors of ASCENDIS PHARMA A/S.
As of August 8, 2016, Scott Thomas Smith is registered as director of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2015. Revenue came to DKK 8,118,000, and the net result was DKK -32,922,000.
As of May 24, 2016, Birgitte Volck has joined the board of directors of ASCENDIS PHARMA A/S.
As of December 7, 2015, Edwin William de Graaf has left the board of directors of ASCENDIS PHARMA A/S.
As of September 25, 2015, Thomas Paul Soloway has stepped down as økonomidirektør of ASCENDIS PHARMA A/S.
As of September 3, 2015, Michael Gerhard Mayer has left the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2014. Revenue came to DKK 13,983,000, and the net result was DKK -9,658,000.
As of November 26, 2014, Jonathan Silverstein has joined the board of directors of ASCENDIS PHARMA A/S.
As of November 26, 2014, Jim Healy has joined the board of directors of ASCENDIS PHARMA A/S.
As of November 26, 2014, Albert Cha has joined the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2013.
As of June 2, 2014, Martin Olin has joined the board of directors of ASCENDIS PHARMA A/S.
As of June 2, 2014, Edwin William de Graaf has joined the board of directors of ASCENDIS PHARMA A/S.
As of April 15, 2014, Dirk Kersten has left the board of directors of ASCENDIS PHARMA A/S.
As of April 1, 2014, William Robert Ringo has left the board of directors of ASCENDIS PHARMA A/S.
As of January 27, 2014, Thomas Paul Soloway is registered as økonomidirektør of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2012. Revenue came to DKK 118,542,000, and the net result was DKK 8,938,000.
As of January 11, 2013, William Robert Ringo has joined the board of directors of ASCENDIS PHARMA A/S.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ASCENDIS PHARMA A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of ASCENDIS PHARMA A/S.
As of January 16, 2008, Michael Wolff Jensen has joined the board of directors of ASCENDIS PHARMA A/S.
As of January 16, 2008, Rafaèle Elisabeth Tordjman has joined the board of directors of ASCENDIS PHARMA A/S.
As of December 11, 2007, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of ASCENDIS PHARMA A/S.
As of December 11, 2007, ApS KBUS 38 NR. 4347 has stepped down as auditor of ASCENDIS PHARMA A/S.
As of December 11, 2007, Jan Møller Mikkelsen has joined the board of directors of ASCENDIS PHARMA A/S.
As of December 11, 2007, Dirk Kersten has joined the board of directors of ASCENDIS PHARMA A/S.
As of December 11, 2007, Michael Gerhard Mayer has joined the board of directors of ASCENDIS PHARMA A/S.
On December 11, 2007, the company changed its name from ASCENDIS PHARMA ApS to ASCENDIS PHARMA A/S.
As of November 27, 2007, ApS KBUS 38 NR. 4347 has been appointed auditor of ASCENDIS PHARMA A/S.
As of November 27, 2007, JUT NR. 2180 A/S has stepped down as auditor of ASCENDIS PHARMA A/S.
As of November 27, 2007, Jan Møller Mikkelsen is registered as adm. dir. of ASCENDIS PHARMA A/S.
As of November 27, 2007, Rigele Abilock has stepped down as adm. dir. of ASCENDIS PHARMA A/S.
On November 27, 2007, the company changed its name from CADENZA PARTNERS ApS to ASCENDIS PHARMA ApS.
As of September 21, 2006, JUT NR. 2180 A/S has been appointed auditor of ASCENDIS PHARMA A/S.
As of September 21, 2006, Rigele Abilock is registered as adm. dir. of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S was founded on September 21, 2006.
Companies in the same industry and area
CVR 32323502
CVR 32323537
CVR 32323596
CVR 32323677
CVR 41034076
companydata.dk